BCL2 and acute myeloid leukemia: On one front, the combination of demethylating agents with the BCL-2 inhibitor Venetoclax has demonstrated benefit in the elderly and those unsuitable for intensive therapy [44, 45], and a multitude of clinical trials are investigating the safety and efficacy of multi-targeted drug combinations for the treatment of relapsed and refractory AML [46, 47].